Antiviral Combination Therapy Global Market Report 2024

The antiviral combination therapy market has grown strongly in recent years. It will grow from $51.15 billion in 2023 to $54.5 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%.The growth observed during the historical period can be attributed to several factors. These include a rise in viral infections, a growing preference among patients for combination treatments, the emergence of drug resistance, advancements in the fields of virology and immunology, and the implementation of global healthcare initiatives. Collectively, these factors contributed to the expansion of the market for antiviral combination therapies during the historical timeframe.

The antiviral combination therapy market is expected to see strong growth in the next few years. It will grow to $71.16 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The anticipated growth in the upcoming period can be attributed to several key factors. These include the ongoing threat of viral infections, increased investments in research and development, a focus on global health preparedness, the adoption of patient-centric approaches, and the potential expansion into new viral indications. Major trends expected in the forecast period encompass the integration of nanotechnology, the conduct of clinical trials to explore innovative combinations, collaborative efforts in research and development, the application of artificial intelligence in drug discovery processes, and strategic initiatives aimed at overcoming drug resistance. These trends are poised to influence and drive growth in the market for antiviral combination therapies.

The surge in viral diseases' occurrences is poised to drive the expansion of the antiviral combination therapy market in the forthcoming years. Viral diseases, stemming from microscopic infectious agents known as viruses, necessitate effective treatment approaches. Antiviral combination therapies play a crucial role in mitigating drug resistance risks and bolstering treatment efficiency. For instance, as of June 2022, the World Health Organization (WHO) reported a staggering 354 million individuals globally afflicted by hepatitis B or C infections, with an annual influx of 1.5 million new hepatitis C cases. This surge in viral infections underscores the imperative for advanced antiviral combination therapies to address these escalating health challenges.

The escalating demand for personalized medicine is set to fuel the growth of the antiviral combination therapy market. Personalized medicine, tailored to an individual's genetic or protein makeup, revolutionizes disease prevention, detection, and treatment. Variances in genetic compositions among individuals influence responses to antiviral therapies, prompting the need to identify these distinctions and optimize treatment strategies. For instance, in 2022, the US Food and Drug Administration (FDA) greenlit 12 personalized medicines, constituting roughly 34% of all newly approved therapeutic molecular entities, as highlighted by the Personalized Medicine Coalition. This burgeoning demand underscores the significance of tailoring treatment approaches, fostering the rise of the antiviral combination therapy market.

The market for antiviral combination therapy sees a rising focus on product innovation. Key companies are actively engaged in developing novel technological solutions to fortify their market standing. Gilead Sciences, Inc., a US-based biopharmaceutical firm, received FDA approval in December 2022 for Sunlenca (lenacapavir) in combination with other antiretroviral(s) to treat heavily treatment-experienced (HTE) adults with multi-drug-resistant (MDR) HIV-1 infection.

Prominent entities in the antiviral combination therapy sphere are prioritizing innovative approaches such as AT-527 to maintain their market presence. AT-527, a nucleotide prodrug, effectively hampers RNA virus replication, including SARS-CoV-2 responsible for COVID-19. In October 2021, Atea Pharmaceuticals, a US-based company, unveiled promising outcomes from a Phase 2 clinical trial of AT-527, an oral, direct-acting antiviral aimed at restraining SARS-CoV-2's replication. This drug holds potential as a new treatment avenue for COVID-19 patients and is part of Atea Pharmaceuticals' line of antiviral products for severe viral infections such as COVID-19 and hepatitis C virus (HCV).

In February 2023, Tonix Pharmaceuticals Holding Corporation, a US-based pharmaceutical company specializing in the development of novel therapies and vaccines for central nervous system disorders and infectious diseases, successfully acquired a preclinical infectious disease portfolio from Healion Bio Inc. for $1.2 million. This strategic acquisition is aimed at expanding Tonix Pharmaceuticals' overall portfolio, incorporating a range of next-generation antiviral technology assets. The newly acquired assets include a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. These candidates can be utilized either as monotherapy or in combination with other antivirals. Healion Bio Inc., the source of the acquired portfolio, is a US-based biotechnology company dedicated to the manufacturing and development of medicines for the treatment and prevention of infectious diseases.

Major companies operating in the antiviral combination therapy market report are AbbVie Inc., Bristol-Myers Squibb Company, Celltrion Inc., Cipla Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Janssen Global Services LLC, Merck & Co. Inc., Mylan N.V., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Novartis International AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Atea Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, Moderna Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vir Biotechnology Inc., Johnson & Johnson, Roche Holding AG, Sun Pharmaceutical Industries Ltd., Hetero Drugs Limited, Macleods Pharmaceuticals Ltd., Emcure Pharmaceuticals Ltd., AuroMedics Pharma LLC, Alembic Pharmaceuticals Limited, Zydus lifescience Ltd., Strides Pharma Science Limited, Glenmark Pharmaceuticals Inc., Lupin Pharmaceuticals Inc.

North America was the largest region in the antiviral combination therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global antiviral combination therapy market report during the forecast period. The regions covered in the antiviral combination therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antiviral combination therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of antiviral combination therapy are branded and generic. Branded antiviral combination therapies are medications manufactured and marketed under a specific brand name by the manufacturer, holding regulatory approval through a new drug application. These formulations typically consist of a combination of two or more antiviral agents and are employed in treating diverse viral infections, including Human Immunodeficiency Virus (HIV), hepatitis C, and influenza. Examples of branded antiviral combination therapies include Atripla, Harvoni, Complera, Symfi Lo, and Xofluza. These combinations incorporate various drug classes, such as nucleotide reverse transcriptase inhibitors, non-nucleotide reverse transcriptase inhibitors, integrase inhibitors, nucleotide reverse transcriptase inhibitors, and protease inhibitors. They are administered through oral and intravenous routes and are distributed through hospital pharmacies, retail pharmacies, and other channels for the treatment of human immunodeficiency virus, hepatitis, and other viral indications.

The antiviral combination therapy market research report provides antiviral combination therapy market statistics, including the antiviral combination therapy industry’s global market size, regional shares, competitors with an antiviral combination therapy market share, detailed antiviral combination therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the antiviral combination therapy industry. This antiviral combination therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antiviral combination therapy market consists of sales of protease inhibitors, reverse transcriptase inhibitors and integrase inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.